Therapeutic strategies to correct proteostasis-imbalance in chronic obstructive lung diseases

Current Molecular Medicine

Volumn 12, Issue 7, 2012, Pages 807-814

  Bodas, M ^a   Tran, I ^a   Vij, N ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Autophagy; Chronic obstructive pulmonary disease (COPD); Cigarette smoke (CS); Emphysema; Proteostasis imbalance; Proteostasis regulators

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA1; TRANSMEMBRANE CONDUCTANCE REGULATOR; UBIQUITIN;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; LUNG FIBROSIS; OXIDATIVE STRESS; PROTEIN DEGRADATION; PROTEIN HOMEOSTASIS; SIGNAL TRANSDUCTION;

EID: 84863506784     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412801318809     Document Type: Article

References (82)

1. Barnes PJ. New concepts in chronic obstructive pulmonary disease. Annu Rev Med 2003; 54: 113-29.
2. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 2006; 28: 219-42.
3. Barnes PJ, Shapiro SD and Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22: 672-88.
4. Yoshida T, Tuder RM. Pathobiology of cigarette smoke induced chronic obstructive pulmonary disease. Physiol Rev 2007; 87: 1047-82.
5. Filosto S, Castillo S, Danielson A, et al. Neutral sphingomyelinase 2: a novel target in cigarette smoke induced apoptosis and lung injury. Am J Respir Cell Mol Biol 2011; 44: 50-60.
6. Balch WE, Morimoto RI, Dillin A and Kelly JW. Adapting proteostasis for disease intervention. Science 2008; 319: 916-9.
7. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007; 8 Suppl 1: S3.
8. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75: 333-66.
9. Min T, Bodas M, Mazur S and Vij N. Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. J Mol Med (Berl) 2011; 89: 577-93.
10. Bartoszewski R, Rab A, Fu L, Bartoszewska S, Collawn J and Bebok Z. CFTR expression regulation by the unfolded protein response. Methods Enzymol 2011; 491: 3-24.
11. Caito S, Rajendrasozhan S, Cook S, et al. SIRT1 is a redoxsensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. Faseb J 2010; 24: 3145-59.
12. Vij N. AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential. J Cell Mol Med 2008; 12: 2511-8.
13. Tanaka K, Chiba T. The proteasome: a protein-destroying machine. Genes Cells 1998; 3: 499-510.
14. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-65.
15. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest 2002; 82: 965-80.
16. Bodas M, Min T and Vij N. Early-age-related changes in proteostasis augment immunopathogenesis of sepsis and acute lung injury. PLoS One 2010; 5: e15480.
17. Gaczynska M, Rock KL and Goldberg AL. Role of proteasomes in antigen presentation. Enzyme Protein 1993; 47: 354-69.
18. Breusing N, Grune T. Regulation of proteasome-mediated protein degradation during oxidative stress and aging. Biol Chem 2008; 389: 203-9.
19. Bodas M, Min T and Vij N. Critical role of CFTR dependent lipid-rafts in cigarette smoke induced lung epithelial injury. Am J Physiol Lung Cell Mol Physiol 2011; 300: L811-820.
20. Chen ZH, Lam HC, Jin Y, et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc Natl Acad Sci USA 2010; 107: 18880-5.
21. Gooptu B, Ekeowa UI and Lomas DA. Mechanisms of emphysema in alpha1-antitrypsin deficiency: molecular and cellular insights. Eur Respir J 2009; 34: 475-88.
22. Bodas M, Min T, Mazur S and Vij N. Critical modifier role of membrane-cystic fibrosis transmembrane conductance regulator-dependent ceramide signaling in lung injury and emphysema. J Immunol 2011; 186: 602-13.
23. Teichgraber V, Ulrich M, Endlich N, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008; 14: 382-91.
24. MacNee W. Oxidants and COPD. Curr Drug Targets Inflamm Allergy 2005; 4: 627-41.
25. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207.
26. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-66.
27. Janoff A. Elastases and emphysema. Current assessment of the protease-antiprotease hypothesis. Am Rev Respir Dis 1985; 132: 417-33.
28. Turino GM, Seniorrm, Garg BD, Keller S, Levi MM and Mandl I. Serum elastase inhibitor deficiency and alpha 1-antitrypsin deficiency in patients with obstructive emphysema. Science 1969; 165: 709-11.
29. Atkinson JJ, Lutey BA, Suzuki Y, et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2011; 183: 876-84.
30. Churg A, Wang RD, Xie C and Wright JL. alpha-1-Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med 2003; 168: 199-207.
31. Mahadeva R, Atkinson C, Li Z, et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166: 377-86.
32. Mulgrew AT, Taggart CC, Lawless MW, et al. Z alpha1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004; 125: 1952-7.
33. Lawless MW, Greene CM, Mulgrew A, Taggart CC, O'Neill SJ and McElvaney NG. Activation of endoplasmic reticulumspecific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol 2004; 172: 5722-6.
34. Adcock IM, Caramori G and Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011;81: 265-84.
35. Yang IA, Relan V, Wright CM, et al. Common pathogenic mechanisms and pathways in the development of COPD and lung cancer. Expert Opin Ther Targets 2011; 15: 439-56.
36. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32: 517-30.
37. Davies AM, Lara PN, Jr., Mack PC and Gandara DR. Incorporating bortezomib into the treatment of lung cancer. Clin Cancer Res 2007; 13: s4647-51.
38. Yuan BZ, Chapman J and Reynolds SH. Proteasome inhibitors induce apoptosis in human lung cancer cells through a positive feedback mechanism and the subsequent Mcl-1 protein cleavage. Oncogene 2009; 28: 3775-86.
39. Escobar M, Velez M, Belalcazar A, Santos ES and Raez LE. The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol 2011; 2011: 806506.
40. Fanucchi MP, Fossella FV, Belt R, et al. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 5025-33.
41. Ruschak AM, Slassi M, Kay LE and Schimmer AD. Novel Proteasome Inhibitors to Overcome Bortezomib Resistance. J Natl Cancer Inst 2011; 103 (13): 1007-17.
42. Valle CW, Min T, Bodas M et al. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One 2011; (6): e29073.
43. Weiss CH, Budinger GR, Mutlu GM and Jain M. Proteasomal regulation of pulmonary fibrosis. Proc Am Thorac Soc 2010; 7: 77-83.
44. Zhao J, Shi W, Wang YL, et al. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 282: L585-93.
45. Sime PJ, O'Reilly KM. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol 2001; 99: 308-19.
46. Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112: 1776-84.
47. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005; 166: 1321-32.
48. Forte A, Della Corte A, De Feo M, Cerasuolo F and Cipollaro M. Role of myofibroblasts in vascular remodelling: focus on restenosis and aneurysm. Cardiovasc Res 2010; 88: 395-405.
49. Izzi L, Attisano L. Regulation of the TGFbeta signalling pathway by ubiquitin-mediated degradation. Oncogene 2004; 23: 2071-8.
50. Vij N. The case for therapeutic proteostasis modulators. Expert Opin Ther Targets 2011; 15: 233-6.
51. Adenuga D, Yao H, March TH, Seagrave J and Rahman I. Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke. Am J Respir Cell Mol Biol 2009; 40: 464-73.
52. Arunachalam G, Yao H, Sundar IK, Caito S and Rahman I. SIRT1 regulates oxidant-and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem Biophys Res Commun 2010; 393: 66-72.
53. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 200-5.
54. van Hees HW, Ottenheijm CA, Ennen L, Linkels M, Dekhuijzen R and Heunks LM. Proteasome inhibition improves diaphragm function in an animal model for COPD. Am J Physiol Lung Cell Mol Physiol 2011; 301 (1): L110-6.
55. Malhotra D, Thimmulappa R, Vij N, et al. Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 2009; 180: 1196-207.
56. Powers ET, Morimoto RI, Dillin A, Kelly JW and Balch WE. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 2009; 78: 959-91.
57. Ben-Zvi A, Miller EA and Morimoto RI. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci USA 2009; 106: 14914-9.
58. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009;135: 173-80.
59. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10: 524-30.
60. Zhao H, Yang J, Shan L and Jorgensen ED. Measuring the impact of cigarette smoke on the UPR. Methods Enzymol 2011; 489: 147-64.
61. Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010;12: 863-75.
62. Johnston JA, Ward CL and Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998;143: 1883-98.
63. Wang Z, Figueiredo-Pereira ME. Inhibition of sequestosome 1/p62 up-regulation prevents aggregation of ubiquitinated proteins induced by prostaglandin J2 without reducing its neurotoxicity. Mol Cell Neurosci 2005; 29: 222-31.
64. Kraft C, Peter M and Hofmann K. Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 2010; 12: 836-41.
65. Levine B, Mizushima N and Virgin HW. Autophagy in immunity and inflammation. Nature 2011; 469: 323-35.
66. Chen ZH, Lam HC, Jin Y, et al. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc Natl Acad Sci USA 2010; 107: 18880-5.
67. Ryter SW, Lam HC, Chen ZH and Choi AM. Deadly triplex: Smoke, autophagy, and apoptosis. Autophagy 2011; 7 (4): 436-7.
68. Monick MM, Powers LS, Walters K, et al. Identification of an autophagy defect in smokers' alveolar macrophages. J Immunol 2010; 185: 5425-35.
69. Martinez-Solano L, Macia MD, Fajardo A, Oliver A and Martinez JL. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008; 47: 1526-33.
70. Bomberger JM, Ye S, Maceachran DP, et al. A Pseudomonas aeruginosa toxin that hijacks the host ubiquitin proteolytic system. PLoS Pathog 2011; 7: e1001325.
71. Vij N, Min T, Marasigan R, et al. Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis. J Nanobiotechnology 2010; 8: 22.
72. Perlmutter DH. The role of autophagy in alpha-1-antitrypsin deficiency: a specific cellular response in genetic diseases associated with aggregation-prone proteins. Autophagy 2006; 2: 258-63.
73. Burrows JA, Willis LK and Perlmutter DH. Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency. Proc Natl Acad Sci USA 2000; 97: 1796-801.
74. Hutt DM, Herman D, Rodrigues AP, et al. Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis. Nat Chem Biol 2010; 6: 25-33.
75. Vij N, Mazur S, Bodas M, Min T. Class-II HDAC inhibition controls P. aeruginosa LPS induced CF lung disease by modulating NFkB signaling, neutrophil chemotaxis and Treg recruitment. North American Cystic Fibrosis Foundation Conference. 2010; Baltimore, MD.
76. Fineschi S, Bongiovanni M, Donati Y, et al. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 2008; 39: 458-65.
77. Fineschi S, Reith W, Guerne PA, Dayer JM and Chizzolini C. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase-1 and up-regulating metalloproteinase-1 production in human dermal fibroblasts. Faseb J 2006; 20: 562-4.
78. Boyce M, Bryant KF, Jousse C, et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307: 935-9.
79. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329: 229-32.
80. Kolb M, Martin G, Medina M, Ask K and Gauldie J. Gene therapy for pulmonary diseases. Chest 2006; 130: 879-84.
81. Vij N. Nano-based theranostics for chronic obstructive lung diseases: challenges and therapeutic potential. Expert Opin Drug Deliv 2011; 8: 1105-9.
82. Roy I, Vij N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 2010; 6: 237-44.